Hematological Malignancies clinical trials at UCSF

• Compassionate Use Study of Tenalisib (RP6530)

  Sorry, accepting new patients by invitation only

  Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.

  San Francisco, California and other locations

Last updated: August 14, 2020